Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

Share Price is delayed by 15 minutes
Get Live Data
1,078.50    26.00 (2.47%)
Bid:
1,071.00
Ask:
1,072.00
Spread: 1.00 (0.093%)
Market Cap: £3.46b
PSN Live PriceLast checked at - London Stock Exchange

Intraday Persimmon Share Chart

Interim Management Statement

15 Nov 2010 07:00

RNS Number : 1376W
Persimmon PLC
15 November 2010
 

 

 

INTERIM MANAGEMENT STATEMENT

 

MONDAY 15 NOVEMBER 2010

 

 

 

Persimmon plc today releases its Interim Management Statement which covers the period from 1 July 2010 to 15 November 2010 and confirms current trading in line with expectations.

 

Since 1 July 2010, sales volumes have remained stable with sales prices and margins holding firm. Although weekly sales increased gradually during September, we did not experience the normal autumn increase in visitor levels and reservations. Cancellation rates remain at a low level of c. 19%.

 

As previously stated at the time of our Half Year Results announcement, we anticipate increasing our sales revenues by c. 10% this year. We expect to legally complete c. 9,400 homes for the year ending 31 December 2010 (2009: 8,976), an increase of c. 5%. We have continued to generate good levels of free cash and now expect that total borrowings at the year end will be lower than £80 million, well ahead of previous guidance.

 

Consistent with our stated strategy of focusing on improving margins, we expect to increase underlying operating margin for the full year to c. 8% (2009: 4%).

 

Mortgage availability remains a major obstacle for customers who wish to purchase a home, especially first time buyers who do not have the required large deposits. Further recovery in industry output and sales will be dependent upon an increase in the supply of mortgage products on appropriate terms.

 

However, we are fully sold up for the current year and we are in a strong financial position with over £460 million of sales already reserved beyond 2010 (2009: £500 million). Our new site starts are proceeding as planned with 60 new sites opened so far through the second half with another 15 to come through by the end of November. This will maintain the strength of our sales network at c. 380 active sites into the New Year. The outlook for sales and volumes for the full year of 2011 is as usual dependent upon the forthcoming spring selling season.

 

We have remained selective in our land replacement since the half year and have acquired c. 4,000 new plots on 41 sites so far in the second half, including c. 20% of plots from our strategic landbank. These investments continue to be made at good margins and will offer excellent returns to the business over the medium term. We also continue to improve the quality of our existing landbank in support of the delivery of improving underlying operating margins.

 

In summary, we expect our performance for 2010 to demonstrate the progress we have made in pursuing our strategy of operating margin improvement and growth in operating cash generation. With the strength of our balance sheet and high quality land holdings we will continue to successfully develop our business in these challenging markets.

 

We will give a further update on progress and trading following the year end on Monday 10 January 2011.

 

For further information, please contact:

 

Edward Orlebar

Charlotte McMullen

Marylène Guernier

Mike Farley, Group Chief Executive

Mike Killoran, Group Finance Director

Persimmon plc

M:Communications

Tel: +44 (0) 1904 642199

Tel: +44 (0) 20 7920 2369

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUUABRRWAAAAA
Date   Source Headline
1st May 20257:00 amRNSAGM Trading Statement
25th Apr 202510:54 amRNSHolding(s) in Company
25th Apr 20259:24 amRNSHolding(s) in Company
11th Apr 20254:22 pmRNSHolding(s) in Company
3rd Apr 202510:15 amRNSHolding(s) in Company
2nd Apr 202512:22 pmRNSHolding(s) in Company
1st Apr 202512:03 pmRNSTotal Voting Rights
31st Mar 20253:14 pmRNSDirector/PDMR Shareholding
27th Mar 202510:08 amRNSHolding(s) in Company
25th Mar 20253:14 pmRNSDirector/PDMR Shareholding
24th Mar 20253:35 pmRNSAnnual Report 2024 and Notice of AGM 2025
24th Mar 20252:24 pmRNSHolding(s) in Company
11th Mar 20257:00 amRNSFull Year Results
6th Mar 20252:06 pmRNSHolding(s) in Company
3rd Mar 20253:35 pmRNSHolding(s) in Company
3rd Feb 202512:26 pmRNSTotal Voting Rights
14th Jan 20257:00 amRNS2024 Trading Statement
2nd Jan 20251:00 pmRNSTotal Voting Rights
10th Dec 20243:47 pmRNSDirectorate Change
2nd Dec 20242:11 pmRNSBlock listing Interim Review
2nd Dec 202412:00 pmRNSTotal Voting Rights
6th Nov 20247:00 amRNSQ3 Trading Statement
5th Nov 20241:31 pmRNSHolding(s) in Company
1st Nov 20243:59 pmRNSTotal Voting Rights
1st Oct 20241:19 pmRNSTotal Voting Rights
24th Sep 202412:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20241:44 pmRNSTotal Voting Rights
8th Aug 20247:00 amRNSHalf Year Results
1st Aug 20242:32 pmRNSTotal Voting Rights
23rd Jul 202410:28 amRNSDirectorate Change
1st Jul 20241:10 pmRNSTotal Voting Rights
19th Jun 20242:48 pmRNSDirector/PDMR Shareholding
3rd Jun 202412:33 pmRNSBlock listing Interim Review
3rd Jun 202411:08 amRNSTotal Voting Rights
23rd May 20247:00 amRNSConfirmation of CFO start date
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.